Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
VVC Exploration Corporation Provides Regulatory Update and Clarifies a Previous Incorrect Statement about CYRB
